Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin

OBJECTIVES: To study glibenclamide as a treatment for gestational diabetes mellitus (GDM) and its impact on newborn birth weight and neonatal glycemia as compared to insulin. METHODS: A randomized and open-label clinical trial, conducted from October 1st, 2003 to March 8, 2005. Seventy-two pregnant women with gestational diabetes mellitus requiring drug therapy were randomized and allocated into two groups - insulin and glibenclamide. RESULTS: The general characteristics in both groups were similar, except for the results of the 75 g OGTT, which were higher in the glibenclamide group (p= 0.02). Maternal fasting and postprandial glucose levels presented no difference. Six (18.75%) pregnant women received the maximum dose of glibenclamide with no glycemic control. The birth weight was higher in the group treated with glibenclamide (p= 0.01), and the incidence of macrosomic newborns statistically different (p= 0.01). Neonatal hypoglycemia was more frequent (p= 0.01) in newborns of glibenclamide group, with one single case of persistent hypoglycemia. CONCLUSION: Glibenclamide can be the first line drug for glycemic control in most GDM patients. The birth weight and incidence of hypoglycemia were higher in the glibenclamide group, but with one single case of persistent hypoglycemia that required intravenous infusion of glucose.OBJETIVOS: Estudar a glibenclamida no tratamento do diabete melito gestacional (DMG) e sua repercussão no peso e na glicemia do recém-nascido (RN), em comparação com a insulina. MÉTODOS: Ensaio clínico randomizado e aberto, realizado entre 1º de outubro de 2003 e 8 de março de 2005. Foram sujeitas 72 gestantes com DMG que necessitaram de terapêutica complementar, sendo randomizadas em dois grupos: insulina e glibenclamida. RESULTADOS: As características gerais nos grupos não apresentaram diferença estatística, com exceção dos resultados do TTOG 75 g, que apresentaram valores maiores no grupo da glibenclamida (p= 0,02). As glicemias médias maternas não apresentaram diferença. Seis (18,75%) gestantes atingiram a dose máxima de glibenclamida sem o controle glicêmico. O peso dos RNs foi maior no grupo tratado com glibenclamida (p= 0,01), com diferença na incidência de macrossômico (p= 0,01). A hipoglicemia neonatal estava mais presente (p= 0,01) nos RNs do grupo da glibenclamida, porém com apenas um caso de hipoglicemia persistente. CONCLUSÃO: A glibenclamida pode ser a droga de escolha para tratamento do DMG na maioria das pacientes.Universidade Federal de São Paulo (UNIFESP) EPM Departamento de ObstetríciaMaternidade Darcy VargasUniversidade da Região de JoinvilleUNIFESP, EPM, Depto. de ObstetríciaSciEL

The seesaw mechanism at TeV scale in the 3-3-1 model with right-handed neutrinos

We implement the seesaw mechanism in the 3-3-1 model with right-handed neutrinos. This is accomplished by the introduction of a scalar sextet into the model and the spontaneous violation of the lepton number. We identify the Majoron as a singlet under $SU_L(2)\otimes U_Y(1)$ symmetry, which makes it safe under the current bounds imposed by electroweak data. The main result of this work is that the seesaw mechanism works already at TeV scale with the outcome that the right-handed neutrino masses lie in the electroweak scale, in the range from MeV to tens of GeV. This window provides a great opportunity to test their appearance at current detectors, though when we contrast our results with some previous analysis concerning detection sensitivity at LHC, we conclude that further work is needed in order to validate this search.Comment: about 13 pages, no figure

Exciton Spin Dynamics in Semiconductor Quantum Wells

In this paper we will review Exciton Spin Dynamics in Semiconductor Quantum Wells. The spin properties of excitons in nanostructures are determined by their fine structure. We will mainly focus in this review on GaAs and InGaAs quantum wells which are model systems.Comment: 55 pages, 27 figure

On the reliability of a simple method for scoring phenotypes to estimate heritability: A case study with pupal color in Heliconius erato phyllis, Fabricius 1775 (Lepidoptera, Nymphalidae)

In this paper, two methods for assessing the degree of melanization of pupal exuviae from the butterfly Heliconius erato phyllis, Fabricius 1775 (Lepidoptera, Nymphalidae, Heliconiini) are compared. In the first method, which was qualitative, the exuviae were classified by scoring the degree of melanization, whereas in the second method, which was quantitative, the exuviae were classified by optical density followed by analysis with appropriate software. The heritability (h2) of the degree of melanization was estimated by regression and analysis of variance. The estimates of h 2 were similar with both methods, indicating that the qualitative method could be particularly suitable for field work. The low estimates obtained for heritability may have resulted from the small sample size (n = 7-18 broods, including the parents) or from the allocation-priority hypothesis in which pupal color would be a lower priority trait compared to morphological traits and adequate larval development